Covid-19 roundup: Trump back­tracks on NIH/CDC fund­ing, No­var­tis launch­es $20M fund, FDA and ICER can­cel­la­tions

6 years ago
R&D
Coronavirus

Bris­tol My­ers CEO Caforio hires a top in­vest­ment banker from Bar­clays for his next BD/strat­e­gy chief

6 years ago
People

TCR play­er Im­mat­ics com­bines with Per­cep­tive’s blank check op­er­a­tor, scoop­ing $252M and gain­ing a list­ing on Nas­daq

6 years ago
Deals
R&D

Covid-19 could throw fi­nal hur­dle in­to Ab­b­Vie and Al­ler­gan’s mas­sive merg­er

6 years ago
Deals
R&D

As Covid-19 R&D goes in­to over­drive, nuts-and-bolts bio­phar­ma re­search is hit­ting the skids. How bad is it?

6 years ago
R&D
Coronavirus

For­mer Shire ex­ecs set up shop to take a shot at 'un­der the radar' can­cer tar­get

6 years ago
Financing
Startups

Con­tract man­u­fac­tur­er: FDA has halt­ed do­mes­tic phar­ma in­spec­tions

6 years ago
FDA+
Coronavirus

The big C: The deal­mak­ers, dol­lars and dis­eases that have trans­formed the Chi­nese bio­phar­ma mar­ket

6 years ago
Financing
Deals

UK takes tougher stance to com­bat coro­n­avirus, as pre­vi­ous ap­proach risks hun­dreds of thou­sands of lives — study

6 years ago
Coronavirus

Rick Klaus­ner's Lyell part­ners, helps fund Eu­reka's work on cell ther­a­pies; Blue­print bounces high­er on PhII

6 years ago
News Briefing

Mer­ck touts PhI­II da­ta bur­nish­ing $500M plat­form — what kind of bar does it set for a chron­ic cough drug?

6 years ago
R&D

Safe­ty is­sues force No­vo Nordisk to shut­ter PhI­II he­mo­phil­ia tri­als

6 years ago
R&D

‘Pa­tient ze­ro’ in Ten­nessee talks about fear, anx­i­ety, hys­te­ria and count­less acts of kind­ness as the Bio­gen ...

6 years ago
People
Coronavirus

Flag­ship’s Sig­ilon grabs $80M to bring Robert Langer cell ther­a­py tech in­to the clin­ic

6 years ago
Financing

Covid-19 roundup — Re­gen­eron zooms in on cock­tail; BioN­Tech shares sky­rock­et on quick Pfiz­er al­liance

6 years ago
Coronavirus

As­traZeneca says that treme flubbed an­oth­er com­bo can­cer study, rais­ing fresh doubts about a se­r­i­al los­er

6 years ago
R&D

In an­oth­er win for ri­val Aim­mune, FDA press­es pause on DB­V's peanut patch with ad­di­tion­al ques­tions

6 years ago
R&D

‘It’s like the tor­toise and the hare’: A pan­dem­ic puts Sanofi’s $600M bet to the test

6 years ago
R&D
Coronavirus

Five days af­ter re­gain­ing the helm at Cure­Vac — and 1 day af­ter con­tro­ver­sy erupt­ed — In­g­mar Ho­err makes sur­prise ...

6 years ago
People

An­oth­er an­tibi­ot­ic mak­er bites the dust, as Tetraphase is swal­lowed for cheap

6 years ago
Deals
Pharma

Bio­gen staffer fled to Chi­na in search of emer­gency Covid-19 test­ing, care — and now faces crim­i­nal charges

6 years ago
People
Coronavirus

EMA of­fers free sci­en­tif­ic ad­vice for Covid-19 de­vel­op­ers

6 years ago
Coronavirus

Unum gets a re­prieve from the FDA — par­tial hold lift­ed af­ter 9 days

6 years ago
R&D

'We're led by the sci­ence': UK's plan to de­lay coro­n­avirus peak and pur­sue herd im­mu­ni­ty trig­gers up­roar

6 years ago
Coronavirus
First page Previous page 852853854855856857858 Next page Last page
A service from the Financial Times